Leif Bertilsson - Publications, H-index & Citations

Leif Bertilsson

Karolinska Institutet

85H指数

405论文数

2.3W被引数

收录论文 63

发表时间

Correction: Li et al. Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers. J. Pers. Med. 2021, 11, 457 更正：Li等人. 评估脱氧胆酸1β-羟化作用作为健康受试者中基于抑制的药物-药物相互作用评估中CYP3A活性的非侵入性尿液生物标志物. J. Pers. Med. 2021, 11, 457

Journal of Personalized Medicine

IF3

2026-09-15

OAAI

Xue-Qing Li; Roslyn Stella Thelingwani; Leif Bertilsson; Ulf Diczfalusy; Tommy B. Andersson; Collen Masimirembwa

Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers

JOURNAL OF PERSONALIZED MEDICINE

IF3

2021-05-24

OAAI

Li, Xue-Qing; Thelingwani, Roslyn Stella; Bertilsson, Leif; Diczfalusy, Ulf; Andersson, Tommy B.; Masimirembwa, Collen

Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-07-08

PREAI

Dahl, Marja-Liisa; Bergman, Ulf; Bertilsson, Leif; Eliasson, Erik; Gustafsson, Lars L.; Panagiotidis, Georgios; Rane, Anders

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype

SCIENTIFIC REPORTS

IF3.9

2018-11-05

OAAI

Kitabi, Eliford Ngaimisi; Minzi, Omary Mashiku Sylivester; Mugusi, Sabina; Sasi, Philip; Janabi, Mohamed; Mugusi, Ferdinand; Bertilsson, Leif; Burhenne, Jurgen; Aklillu, Eleni

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-08-01

OAAI

Habtewold, Abiy; Aklillu, Eleni; Makonnen, Eyasu; Yimer, Getnet; Bertilsson, Leif; Burhenne, Juergen; Owen, Joel S.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2014-08-04

OAAI

Ngaimisi, E.; Minzi, O.; Mugusi, S.; Sasi, P.; Riedel, K. -D.; Suda, A.; Ueda, N.; Bakari, M.; Janabi, M.; Mugusi, F.; Bertilsson, L.; Burhenne, J.; Aklillu, E.; Diczfalusy, U.

Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2013-10-01

PREAI

Bertilsson, L.; Hatta, F. H.

UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2012-06-20

PREAI

Haslemo, T.; Loryan, I.; Ueda, N.; Mannheimer, B.; Bertilsson, L.; Ingelman-Sundberg, M.; Molden, E.; Eliasson, E.

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2011-08-03

PREAI

Ngaimisi, E.; Mugusi, S.; Minzi, O.; Sasi, P.; Riedel, K-D; Suda, A.; Ueda, N.; Janabi, M.; Mugusi, F.; Haefeli, W. E.; Bertilsson, L.; Burhenne, J.; Aklillu, E.

4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2011-01-10

190

OAAI

Diczfalusy, Ulf; Nylen, Hanna; Elander, Pontus; Bertilsson, Leif

ACTIVITY OF CYP3A IN MOTHERS AND THEIR NEWBORNS USING 4B-HYDROXYCHOLESTEROL AS A MARKER

PEDIATRIC RESEARCH

IF3.1

2010-11-01

OAAI